94 related articles for article (PubMed ID: 16544144)
1. Effect of CYP2D6 genetic polymorphism on the population pharmacokinetics of tipifarnib.
Perez-Ruixo JJ; Zannikos P; Ozdemir V; Franc MA; Francke S; Piotrovsky V
Cancer Chemother Pharmacol; 2006 Nov; 58(5):681-91. PubMed ID: 16544144
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.
Perez-Ruixo JJ; Piotrovskij V; Zhang S; Hayes S; De Porre P; Zannikos P
Br J Clin Pharmacol; 2006 Jul; 62(1):81-96. PubMed ID: 16842381
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.
Zhang S; Zannikos P; Awada A; Piccart-Gebhart M; Dirix LY; Fumoleau P; Verhaeghe T; Francois M; De Porre P
J Clin Pharmacol; 2006 Oct; 46(10):1116-27. PubMed ID: 16988200
[TBL] [Abstract][Full Text] [Related]
4. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability.
Kerbusch T; Wählby U; Milligan PA; Karlsson MO
Br J Clin Pharmacol; 2003 Dec; 56(6):639-52. PubMed ID: 14616424
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
[TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.
Pawlowska M; Bogiel M; Duda J; Sieradzki E
Eur J Clin Pharmacol; 2015 Jun; 71(6):699-705. PubMed ID: 25953735
[TBL] [Abstract][Full Text] [Related]
8. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
[TBL] [Abstract][Full Text] [Related]
9. Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males.
Koue T; Kubo M; Funaki T; Fukuda T; Azuma J; Takaai M; Kayano Y; Hashimoto Y
Biol Pharm Bull; 2007 Nov; 30(11):2154-8. PubMed ID: 17978491
[TBL] [Abstract][Full Text] [Related]
10. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers.
Borobia AM; Novalbos J; Guerra-López P; López-Rodríguez R; Tabares B; Rodríguez V; Abad-Santos F; Carcas AJ
Pharmacol Res; 2009 Jun; 59(6):393-8. PubMed ID: 19429471
[TBL] [Abstract][Full Text] [Related]
11. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype.
Jaanson P; Marandi T; Kiivet RA; Vasar V; Vään S; Svensson JO; Dahl ML
Psychopharmacology (Berl); 2002 Jun; 162(1):67-73. PubMed ID: 12107620
[TBL] [Abstract][Full Text] [Related]
13. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.
Rogers HL; Bhattaram A; Zineh I; Gobburu J; Mathis M; Laughren TP; Pacanowski M
J Clin Psychiatry; 2012 Sep; 73(9):1187-90. PubMed ID: 23059146
[TBL] [Abstract][Full Text] [Related]
15. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity.
Kirchheiner J; Sasse J; Meineke I; Roots I; Brockmöller J
Pharmacogenetics; 2003 Dec; 13(12):721-8. PubMed ID: 14646691
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
17. No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population.
Scordo MG; Dahl ML; Spina E; Cordici F; Arena MG
Pharmacol Res; 2006 Feb; 53(2):162-5. PubMed ID: 16337409
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
Hendset M; Molden E; Knape M; Hermann M
Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
